DIGITAL THERAPEUTICS FOR ANXIETY AND DEPRESSION: A STRUCTURED REVIEW OF CLINICAL EVIDENCE, REGULATORY FRAMEWORKS, AND ACCESS DISPARITIES
Authors:
- Maryan LiasotaMLMaryan Liasota
- Michalina Justyna KozłowskaMKMichalina Justyna Kozłowska
- Krzysztof KonopkaKKKrzysztof Konopka
- Maciej Kamil MajchrzakMMMaciej Kamil Majchrzak
- Faustyna Magdalena KołodziejFKFaustyna Magdalena Kołodziej
- Alicja KwiatkowskaAKAlicja Kwiatkowska
- Jakub JuskowiakJJJakub Juskowiak
- Mateusz LisMLMateusz Lis
- Zuzanna Julia KominZKZuzanna Julia Komin
- Eliza Zofia KabatEKEliza Zofia Kabat
Open Access
- 7 October 2026
- journal article
- review article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (4(52))
Abstract
Background: The integration of Digital Therapeutics (DTx) into psychiatric care represents a paradigm shift in the management of anxiety and depression. With the continuous technological advancement of Software as a Medical Device (SaMD), its potential to alleviate shortages in psychiatric care is facing rigorous evaluation. As a result, ongoing studies aim to verify whether these technologies deliver genuine medical improvements, while simultaneously exploring the structural hurdles of deploying them within traditional clinical settings. Objective: This structured review evaluates the intersection of clinical evidence for DTx in treating Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD) with existing regulatory frameworks and socioeconomic barriers to equitable access. Methodology: An investigative sweep of the PubMed/MEDLINE and Google Scholar databases was executed to identify literature published from 2018 to 2026. Inclusion criteria focused on peer-reviewed RCTs and policy analyses of evidence-based DTx platforms. The assembled data underwent systematic organization via a thematic approach, with material being classified into three distinct categories: clinical efficacy, regulatory limitations, and accessibility equity. Results: Findings indicate that while AI-driven CBT and chatbot-delivered interventions demonstrate significant symptom reduction with moderate-to-high effect sizes, their long-term efficacy is moderated by user engagement patterns. Regulatory analysis reveals a fragmentation between the US FDA and European DiGA pathways, complicating global reimbursement. Furthermore, structural disparities—driven by the "digital divide" and low technological literacy—persistently limit the reach of these interventions among underserved populations. Conclusion: Digital interventions present an easily expandable mechanism for combating global psychiatric shortages; however, inconsistent legal guidelines and socioeconomic barriers heavily restrict their medical utility. Subsequent academic efforts need to emphasize multidimensional adoption models to prevent these technological advancements from worsening present-day medical inequalities.Keywords
This publication has 24 references indexed in Scilit:
- Use of Technology to Provide Mental Health Care for Racial and Ethnic Minorities: Evidence, Promise, and ChallengesCognitive and Behavioral Practice, 2022
- An overview of and recommendations for more accessible digital mental health servicesNature Reviews Psychology, 2022
- Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemicThe Lancet, 2021
- The growing field of digital psychiatry: current evidence and the future of apps, social media, chatbots, and virtual realityWorld Psychiatry, 2021
- Implementation strategies for digital mental health interventions in health care settings.American Psychologist, 2020
- Germany’s digital health reforms in the COVID-19 era: lessons and opportunities for other countriesnpj Digital Medicine, 2020
- Dropout rates in clinical trials of smartphone apps for depressive symptoms: A systematic review and meta-analysisJournal of Affective Disorders, 2020
- The efficacy of app‐supported smartphone interventions for mental health problems: a meta‐analysis of randomized controlled trialsWorld Psychiatry, 2019
- The Lancet Commission on global mental health and sustainable developmentThe Lancet, 2018
- Empowering the digital therapeutic relationship: virtual clinics for digital health interventionsnpj Digital Medicine, 2018